Identification of the Role of Endogenous Cannabinoids in Pain Modulation: Strategies and Pitfalls

[1]  J. Walker,et al.  Pain modulation by release of the endogenous cannabinoid anandamide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Herkenham,et al.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. Steiner,et al.  Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Kendall,et al.  Involvement of the Carboxyl Terminus of the Third Intracellular Loop of the Cannabinoid CB1 Receptor in Constitutive Activation of Gs , 1999, Journal of neurochemistry.

[5]  P. Casellas,et al.  Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE‐1 isoform via Gi‐mediated mitogen activated protein kinase signaling transduction pathways , 1999, FEBS letters.

[6]  R. Bukoski,et al.  A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca2+-induced relaxation. , 1999, The Journal of pharmacology and experimental therapeutics.

[7]  J. Cheer,et al.  Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors , 1999, Neuropharmacology.

[8]  P. Casellas,et al.  Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. , 1999, Molecular pharmacology.

[9]  P. Casellas,et al.  SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. , 1999, The Journal of pharmacology and experimental therapeutics.

[10]  M. Parmentier,et al.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. , 1999, Science.

[11]  B. Szabo,et al.  Effect of the cannabinoid receptor agonist WIN55212‐2 on sympathetic cardiovascular regulation , 1999, British journal of pharmacology.

[12]  S. L. Patrick,et al.  Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity , 1998, Brain Research.

[13]  F. Fonseca,et al.  Role of the Endogenous Cannabinoid System in the Regulation of Motor Activity , 1998, Neurobiology of Disease.

[14]  S. Ikeda,et al.  SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. , 1998, Molecular pharmacology.

[15]  A. Makriyannis,et al.  Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. , 1998, Biochemical pharmacology.

[16]  A. Urtti,et al.  Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. , 1998, Life sciences.

[17]  R. Beninger,et al.  The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by Δ9-tetrahydrocannabinol or anandamide , 1998, Psychopharmacology.

[18]  G. Gessa,et al.  Inhibition of hippocampal acetylcholine release after acute and repeated Δ9-tetrahydrocannabinol in rats , 1998, Brain Research.

[19]  Richard E. White,et al.  The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery , 1998, British journal of pharmacology.

[20]  H. Fields,et al.  An analgesia circuit activated by cannabinoids , 1998, Nature.

[21]  M. Shen,et al.  Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. , 1998, Molecular pharmacology.

[22]  G. Gessa,et al.  Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. , 1998, European journal of pharmacology.

[23]  C. Guaza,et al.  The endogenous cannabinoid anandamide potentiates interleukin‐6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor‐mediated pathway , 1998, FEBS letters.

[24]  J. Mogil,et al.  Transgenic studies of pain , 1998, Pain.

[25]  P. Soubrié,et al.  Cannabinoids decrease excitatory synaptic transmission and impair long‐term depression in rat cerebellar Purkinje cells , 1998, The Journal of physiology.

[26]  F. Borrelli,et al.  Excitatory transmission to the circular muscle of the guinea‐pig ileum: evidence for the involvement of cannabinoid CB1 receptors , 1998, British journal of pharmacology.

[27]  G. Kunos,et al.  Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  G. Gessa,et al.  Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. , 1998, Life sciences.

[29]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[30]  W. Yung,et al.  Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium , 1998, Neuroscience Letters.

[31]  D. Bonhaus,et al.  Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors , 1998, British journal of pharmacology.

[32]  G. Gessa,et al.  Δ9‐Tetrahydrocannabinol increases sequence‐specific AP‐1 DNA‐binding activity and Fos‐related antigens in the rat brain , 1998, The European journal of neuroscience.

[33]  J. Lowe,et al.  Characterization of Δ9-Tetrahydrocannabinol and Anandamide Antinociception in Nonarthritic and Arthritic Rats , 1998, Pharmacology Biochemistry and Behavior.

[34]  K. Starke,et al.  Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum , 1998, Neuroscience.

[35]  J. D. Richardson,et al.  Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors , 1998, Pain.

[36]  G. Gessa,et al.  Cannabinoid modulation of intestinal propulsion in mice. , 1998, European journal of pharmacology.

[37]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[38]  M. Scanziani,et al.  Dual Effects of Anandamide on NMDA Receptor‐Mediated Responses and Neurotransmission , 1998, Journal of neurochemistry.

[39]  J. Zentner,et al.  Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus Naunyn-Schmiedeberg’s Arch Pharmacol (1997) 356:583–589 , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[40]  G. Gessa,et al.  Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. , 1998, European journal of pharmacology.

[41]  J. D. Richardson,et al.  Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia , 1998, The Journal of Neuroscience.

[42]  J. Ramos,et al.  The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. , 1997, Life sciences.

[43]  D. Piomelli,et al.  Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. , 1997, European journal of pharmacology.

[44]  Richard P. White,et al.  A comparison of EDHF‐mediated and anandamide‐induced relaxations in the rat isolated mesenteric artery , 1997, British journal of pharmacology.

[45]  P. Sacerdote,et al.  Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound , 1997, Journal of Neuroimmunology.

[46]  F. Petitet,et al.  Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study. , 1997, Biochemical pharmacology.

[47]  D. R. Compton,et al.  The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. , 1997, The Journal of pharmacology and experimental therapeutics.

[48]  C. Hiley,et al.  Endothelium and cannabinoid receptor involvement in levcromakalim vasorelaxation. , 1997, European journal of pharmacology.

[49]  J. Brotchie,et al.  The Cannabinoid Receptor Agonist WIN 55,212-2 Reduces D2, but Not D1, Dopamine Receptor-Mediated Alleviation of Akinesia in the Reserpine-Treated Rat Model of Parkinson's Disease , 1997, Experimental Neurology.

[50]  J. Zentner,et al.  Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[51]  I. Yamamoto,et al.  Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. , 1997, Journal of biochemistry.

[52]  H. Yamamura,et al.  SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. , 1997, European journal of pharmacology.

[53]  R. Pertwee,et al.  Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea‐pig ileum , 1997, British journal of pharmacology.

[54]  J. Brodkin,et al.  SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[55]  P. Casellas,et al.  A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.

[56]  G. Velasco,et al.  Δ 9-Tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells , 1997, Brain Research.

[57]  T. Wenger,et al.  Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. , 1997, Biochemical and biophysical research communications.

[58]  R. Pertwee,et al.  Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea‐pig myenteric plexus , 1997, British journal of pharmacology.

[59]  B. Malinowska,et al.  Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[60]  A. Kustka,et al.  Morphine- and anadamide-stimulated nitric oxide production inhibits presynaptic dopamine release , 1997, Brain Research.

[61]  A. Makriyannis,et al.  Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. , 1997, Biochemical pharmacology.

[62]  G. Gessa,et al.  Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. , 1997, European journal of pharmacology.

[63]  E. French.  Δ 9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors , 1997, Neuroscience Letters.

[64]  G. Kunos,et al.  Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. , 1997, Hypertension.

[65]  G. Velasco,et al.  Metabolic stimulation of mouse spleen lymphocytes by low doses of delta9-tetrahydrocannabinol. , 1997, Life sciences.

[66]  S. Gatley,et al.  Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. , 1997, European journal of pharmacology.

[67]  J. Brotchie,et al.  Paradoxical action of the cannabinoid WIN 55,212‐2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices , 1997, British journal of pharmacology.

[68]  S. Burstein,et al.  Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. , 1997, Life sciences.

[69]  J. D. Richardson,et al.  SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. , 1997, European journal of pharmacology.

[70]  F. Rodríguez de Fonseca,et al.  Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety‐like responses in the rat , 1997, Neuroreport.

[71]  G. Bennett,et al.  The analgesic effects of R(+)-WIN 55,212–2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain , 1997, Neuroscience Letters.

[72]  P. Soubrié,et al.  Characterization of CB1 Receptors on Rat Neuronal Cell Cultures: Binding and Functional Studies Using the Selective Receptor Antagonist SR 141716A , 1997, Journal of neurochemistry.

[73]  U. Ungerstedt,et al.  Intrastriatally injected c-fos antisense oligonucleotide interferes with striatonigral but not striatopallidal gamma-aminobutyric acid transmission in the conscious rat. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Pertwee,et al.  Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations. , 1996, European journal of pharmacology.

[75]  R. E. Brown,et al.  Cannabinoid modulation of rat pup ultrasonic vocalizations. , 1996, European journal of pharmacology.

[76]  H. Rosenberg,et al.  Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA , 1996, Brain Research.

[77]  J. Lowe,et al.  Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. , 1996, The Journal of pharmacology and experimental therapeutics.

[78]  G. Kunos,et al.  Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB 1 receptors on peripheral sympathetic nerves , 1996, British journal of pharmacology.

[79]  J. Nash,et al.  Further evidence for the presence of cannabinoid CB1 receptors in guinea‐pig small intestine , 1996, British journal of pharmacology.

[80]  R. Pertwee,et al.  Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder , 1996, British journal of pharmacology.

[81]  S. Childers,et al.  Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes. , 1996, Life sciences.

[82]  C. Ashby,et al.  Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. , 1996, The Journal of pharmacology and experimental therapeutics.

[83]  J. Lowe,et al.  In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. , 1996, The Journal of pharmacology and experimental therapeutics.

[84]  E. Ellis,et al.  Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. , 1996, Biochemical pharmacology.

[85]  R. Knapp,et al.  Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception , 1996, Neuroreport.

[86]  G. Hawksworth,et al.  Further evidence for the presence of cannabinoid CB1 receptors in mouse vas deferens. , 1996, European journal of pharmacology.

[87]  T. Chase,et al.  Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. , 1996, European journal of pharmacology.

[88]  P. Soubrié,et al.  Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. , 1996, Life sciences.

[89]  J. Lowe,et al.  Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[90]  P. Soubrié,et al.  The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat. , 1995, Neuroreport.

[91]  C. Destrade,et al.  Post-test apamin injection suppresses a Kamin-like effect following a learning session in mice. , 1995, Neuroreport.

[92]  P. Casellas,et al.  Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells (*) , 1995, The Journal of Biological Chemistry.

[93]  B. Martin,et al.  Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. , 1995, European journal of pharmacology.

[94]  P. Soubrié,et al.  Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. , 1995, Life sciences.

[95]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[96]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[97]  P. Chidiac,et al.  Inverse agonist activity of beta-adrenergic antagonists. , 1994, Molecular pharmacology.

[98]  F. Borrelli,et al.  Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[99]  K. Mackie,et al.  LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. , 1998, The Journal of pharmacology and experimental therapeutics.

[100]  G. Milligan,et al.  Inverse agonism: pharmacological curiosity or potential therapeutic strategy? , 1995, Trends in pharmacological sciences.

[101]  J. Vivian,et al.  Analgesic, Respiratory and Heart Rate Effects of Cannabinoid and Opioid Agonists in Rhesus Monkeys: Antagonist Effects of Sr 141716a 1,2 , 2022 .